The aegis: platelets as biomarkers of tumor progression.

The aegis: platelets as biomarkers of tumor progression. Biomark Med. 2020 May 28;: Authors: N Augustine T Abstract There is increasing awareness that platelets play a significant role in creating a hypercoagulable environment that mediates tumor progression, beyond their classical hemostatic function. Platelets have heterogenic responses to agonists, and differential release and uptake of bioactive molecules may be manipulated via reciprocal cross-talk with cells of the tumor microenvironment. Platelets thus promote tumor progression by enhancing tumor growth, promoting the development of tumor-associated vasculature and encouraging invasion. In the metastatic process, platelets form the shield that protects tumor cells from high-velocity forces and immunosurveillance, while ensuring the establishment of the pre-metastatic niche. This review presents the complexity of these concepts, considering platelets as biomarkers for diagnosis, prognosis and potentially as therapeutic targets in cancer. PMID: 32462904 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research

Related Links:

Publication date: Available online 14 July 2020Source: Seminars in Cancer BiologyAuthor(s): Rui Caetano Oliveira, Henrique Alexandrino, Maria Augusta Cipriano, Filipe Caseiro Alves, José Guilherme Tralhão
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Source Type: research
Authors: Feng Z, Feng Z, Han J, Cheng W, Su B, Mo J, Feng X, Feng S, Chen G, Huang P, Huang L, Cui Z Abstract Shenling Baizhu additive powder (SLBZ-AP), a formulation of a variety of natural medicinal plants, has clinical efficacy in treating cancers in previous studies. We explored the effect of SLBZ-AP in bone metastasis of lung cancer (BMLC) mice, and the possible mechanism involved was further investigated in the present study. Mice model of BMLC was made and treated with SLBZ-AP. Pain behavioral tests were performed to explore the effect on BMLC-induced pain in mice. TUNEL staining was used to investigate apop...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Publication date: Available online 13 July 2020Source: Materials Today: ProceedingsAuthor(s): Anita Gupta
Source: Materials Today: Proceedings - Category: Materials Science Source Type: research
Publication date: December 2020Source: Materials Today Communications, Volume 25Author(s): Ananda Danagoudar, Pratap G K, Manjula Shantaram, Biji Chatterjee, Krishna Ghosh, Santosh R. Kanade, Chandrashekhar G. Joshi
Source: Materials Today Communications - Category: Materials Science Source Type: research
CONCLUSION: The therapeutic benefit of additional substances is less distinct in patients with RAS mutated as compared to RAS wildtype metastatic colorectal cancer, especially with regard to OS. PMID: 32561975 [PubMed - indexed for MEDLINE]
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
Conclusions: PS ≥ 1, neutrophil count, PLT, andK level were important risk factors for GC therapy-induced hematological toxicity in patients with UC. To continue GC therapy, further management systems by hematological toxicity risk factors for patients with UC will be required.Chemotherapy
Source: Chemotherapy - Category: Cancer & Oncology Source Type: research
Background: Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.Summary: IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular...
Source: Breast Care - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 July 2020Source: Redox BiologyAuthor(s): Hitoshi Endo, Satoshi Owada, Yutaka Inagaki, Yukari Shida, Masayuki Tatemichi
Source: Redox Biology - Category: Biology Source Type: research
Publication date: September 2020Source: Biomedical Signal Processing and Control, Volume 62Author(s): Zakir Hossen, Mohammed Abid Abrar, Sharmin R. Ara, Md. Kamrul Hasan
Source: Biomedical Signal Processing and Control - Category: Biomedical Science Source Type: research
More News: Cancer | Cancer & Oncology | Environmental Health | Internal Medicine